Form 4 filings across 1 company. Net figures count open-market buys and sales only. EDGAR profile ↗
Lifetime net: $0
Reported holding is the most recent post-transaction share count on a Table I row.
How quickly this filer reports. Section 16 allows two business days from the transaction.
All 2 filings we hold were filed within the two-business-day deadline.
Counted in business days from the transaction date, or the deemed execution date where the filing reports one, excluding weekends and federal holidays. How this is measured · All late filings
The 26 most recent Form 4 transactions.
| Dec 9, 2025 | AKRO | Akero Therapeutics, Inc. | DTOISS◆ | 29,074 | — | — | — | Open the original filing on SEC.gov |
| Dec 9, 2025 | AKRO | Akero Therapeutics, Inc. | DTOISS◆ | 29,074 | — | — | — | Open the original filing on SEC.gov |
| Dec 9, 2025 | AKRO | Akero Therapeutics, Inc. | DTOISS◆ | 26,152 | — | — | — | Open the original filing on SEC.gov |
| Dec 9, 2025 | AKRO | Akero Therapeutics, Inc. | DTOISS◆ | 84,051 | — | — | — | Open the original filing on SEC.gov |
| Dec 9, 2025 | AKRO | Akero Therapeutics, Inc. | DTOISS◆ | 119,969 | — | — | — | Open the original filing on SEC.gov |
| Dec 9, 2025 | AKRO | Akero Therapeutics, Inc. | DTOISS◆ | 56,579 | — | — | — | Open the original filing on SEC.gov |
| Dec 9, 2025 | AKRO | Akero Therapeutics, Inc. | DTOISS◆ | 2,328 | — | — | — | Open the original filing on SEC.gov |
| Dec 9, 2025 | AKRO | Akero Therapeutics, Inc. | DTOISS◆ | 5,032 | — | — | — | Open the original filing on SEC.gov |
| Dec 9, 2025 | AKRO | Akero Therapeutics, Inc. | DTOISS◆ | 3,421 | — | — | — | Open the original filing on SEC.gov |
| Dec 9, 2025 | AKRO | Akero Therapeutics, Inc. | DTOISS | 43,810 | — | — | -100.0% | Open the original filing on SEC.gov |
| Dec 9, 2025 | AKRO | Akero Therapeutics, Inc. | DTOISS | 238,339 | — | — | -100.0% | Open the original filing on SEC.gov |
| Nov 25, 2025 | AKRO | Akero Therapeutics, Inc. | MEXER◆ | 4,739 | — | — | — | Open the original filing on SEC.gov |
| Nov 25, 2025 | AKRO | Akero Therapeutics, Inc. | MEXER◆ | 3,527 | — | — | — | Open the original filing on SEC.gov |
| Nov 25, 2025 | AKRO | Akero Therapeutics, Inc. | MEXER◆ | 4,284 | — | — | — | Open the original filing on SEC.gov |
| Nov 25, 2025 | AKRO | Akero Therapeutics, Inc. | MEXER◆ | 43,064 | — | — | — | Open the original filing on SEC.gov |
| Nov 25, 2025 | AKRO | Akero Therapeutics, Inc. | MEXER◆ | 94,268 | — | — | — | Open the original filing on SEC.gov |
| Nov 25, 2025 | AKRO | Akero Therapeutics, Inc. | MEXER◆ | 2,796 | — | — | — | Open the original filing on SEC.gov |
| Nov 25, 2025 | AKRO | Akero Therapeutics, Inc. | MEXER | 4,739 | $21.10 | $100K | +1.7% | Open the original filing on SEC.gov |
| Nov 25, 2025 | AKRO | Akero Therapeutics, Inc. | MEXER | 94,268 | $0.615 | $58K | +51.5% | Open the original filing on SEC.gov |
| Nov 25, 2025 | AKRO | Akero Therapeutics, Inc. | MEXER | 2,796 | $0.615 | $1.7K | +1.6% | Open the original filing on SEC.gov |
| Nov 25, 2025 | AKRO | Akero Therapeutics, Inc. | MEXER | 4,284 | $21.09 | $90.3K | +2.4% | Open the original filing on SEC.gov |
| Nov 25, 2025 | AKRO | Akero Therapeutics, Inc. | MEXER | 43,064 | $6.36 | $274.1K | +32.4% | Open the original filing on SEC.gov |
| Nov 25, 2025 | AKRO | Akero Therapeutics, Inc. | MEXER | 3,527 | $28.35 | $100K | +2.7% | Open the original filing on SEC.gov |
| Nov 17, 2025 | AKRO | Akero Therapeutics, Inc. | GGIFT | 37,100 | — | — | -22.3% | Open the original filing on SEC.gov |